[go: up one dir, main page]

AR003418A1 - Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación. - Google Patents

Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.

Info

Publication number
AR003418A1
AR003418A1 ARP960102465A AR10246596A AR003418A1 AR 003418 A1 AR003418 A1 AR 003418A1 AR P960102465 A ARP960102465 A AR P960102465A AR 10246596 A AR10246596 A AR 10246596A AR 003418 A1 AR003418 A1 AR 003418A1
Authority
AR
Argentina
Prior art keywords
nipecotic
preparation
pharmaceutical composition
enil
methylene
Prior art date
Application number
ARP960102465A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR003418A1 publication Critical patent/AR003418A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención proporciona una nueva composición farmacéutica caracterizada porque comprende (a) R(-)-N-(4,4-di(3-metiltien-2-il)but-3-enil)-nipecótico o una sal farmacéuticamente aceptable de la misma, (b) uno o más antioxidantesf armacéuticamente aceptables en una cantidad suficiente paraestabilizar R(-)-N-(4,4-di(3-metiltien-2-il)but-3-enil)-nipecótico o su sal farmacéuticamente aceptable y (c) opcionalmente un vehículo farmacéuticamenteaceptable y un procedimientopara la preparación de dicha composición.
ARP960102465A 1995-05-05 1996-05-06 Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación. AR003418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK52395 1995-05-05

Publications (1)

Publication Number Publication Date
AR003418A1 true AR003418A1 (es) 1998-08-05

Family

ID=8094516

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102465A AR003418A1 (es) 1995-05-05 1996-05-06 Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.

Country Status (26)

Country Link
US (1) US5866590A (es)
EP (1) EP0830132B1 (es)
JP (1) JP3195360B2 (es)
KR (1) KR100440354B1 (es)
CN (1) CN1092959C (es)
AR (1) AR003418A1 (es)
AT (1) ATE211911T1 (es)
AU (1) AU707508B2 (es)
BR (1) BR9608120A (es)
CA (1) CA2220019C (es)
CZ (1) CZ292256B6 (es)
DE (1) DE69618586T2 (es)
DK (1) DK0830132T3 (es)
EG (1) EG23781A (es)
ES (1) ES2171669T3 (es)
HU (1) HU223075B1 (es)
IL (1) IL118142A (es)
MX (1) MX9708394A (es)
MY (1) MY115016A (es)
NO (1) NO318599B1 (es)
NZ (1) NZ307159A (es)
PL (1) PL183678B1 (es)
PT (1) PT830132E (es)
UA (1) UA43402C2 (es)
WO (1) WO1996034606A1 (es)
ZA (1) ZA963478B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
CA2299464C (en) * 1997-08-01 2009-02-17 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
EP1017386A1 (en) * 1997-10-02 2000-07-12 H. Lundbeck A/S GRANULAR PREPARATIONS OF 5-(2-ETHYL- 2$i(H)-TETRAZOL- 5-YL)-1-METHYL-1, 2,3,6-TETRAHYDROPYRIDINE
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
AU2001260083A1 (en) 2000-05-26 2001-12-03 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
WO2013167986A2 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of epilepsy
EP3342410A4 (en) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION WITH RAPAMYCIN OR DERIVATIVES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US501090A (en) * 1893-07-11 gennert
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies

Also Published As

Publication number Publication date
IL118142A (en) 1999-11-30
MX9708394A (es) 1998-02-28
DE69618586D1 (de) 2002-02-21
EP0830132B1 (en) 2002-01-16
CN1183721A (zh) 1998-06-03
EP0830132A1 (en) 1998-03-25
KR100440354B1 (ko) 2004-09-18
JPH10505359A (ja) 1998-05-26
NZ307159A (en) 1998-10-28
AU5644196A (en) 1996-11-21
CZ338897A3 (cs) 1998-03-18
AU707508B2 (en) 1999-07-15
CN1092959C (zh) 2002-10-23
PT830132E (pt) 2002-07-31
PL183678B1 (pl) 2002-06-28
HUP9802741A2 (hu) 1999-03-29
HU223075B1 (hu) 2004-03-01
JP3195360B2 (ja) 2001-08-06
PL323138A1 (en) 1998-03-16
IL118142A0 (en) 1996-09-12
WO1996034606A1 (en) 1996-11-07
DE69618586T2 (de) 2002-09-05
ZA963478B (en) 1996-11-13
NO975076D0 (no) 1997-11-04
DK0830132T3 (da) 2002-04-29
EG23781A (en) 2007-08-13
US5866590A (en) 1999-02-02
NO318599B1 (no) 2005-04-18
BR9608120A (pt) 1999-02-09
UA43402C2 (uk) 2001-12-17
ES2171669T3 (es) 2002-09-16
ATE211911T1 (de) 2002-02-15
MY115016A (en) 2003-03-31
NO975076L (no) 1997-11-04
CZ292256B6 (cs) 2003-08-13
CA2220019A1 (en) 1996-11-07
CA2220019C (en) 2007-12-11
HUP9802741A3 (en) 1999-04-28

Similar Documents

Publication Publication Date Title
AR003418A1 (es) Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.
ES2123910T3 (es) Composiciones que contienen sales anfoteras de alfa-hidroxiacidos y monocaprilato de glicerol.
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
DE69231674D1 (de) Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv
MX9206851A (es) Sales organicas de n,n'-diacetil cistina, proceso para su preparacion y composicion farmaceutica que las contiene.
ES2097546T3 (es) Preparaciones cosmeticas desodorantes que contienen esteres di- o trigliceridos.
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
MX9300777A (es) Derivados aminoacetilmercapto novedosos utiles como inhibidores de la encefalinasa y la eca
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
ES2098921T3 (es) Composiciones de cetoconazol de uso topico.
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2148593T3 (es) Compuestos retinoides trienoicos novedosos y metodos.
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
DK0710108T3 (da) Flydende, farmaceutisk præparat til oral anvendelse indeholdende 2-(4-isobutylphenyl)-propionsyre
MX171542B (es) Composiciones farmaceuticas que contienen deoxirribonucleosidos para cicatrizacion de heridas
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
AR013559A1 (es) USO DE DERIVADOS DE PIRROLIDINA PARA LA PREPARACIoN DE MEDICAMENNTOS DESTINADOS AL TRATAMIENTO DEL ABUSO DE DROGAS O DE SUSTANCIAS QUE DAN ORIGEN A LA ADICCIoN O AL USO EXCESIVO DE DROGAS , CON EXCEPCIoN DEL ABUSO DEL ALCOHOL, MEDIANTE LA REDUCCIoN DE LA AUTO-MEDICACIoN DE DICHAS DROGAS POR PARTE DE
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
EA200000112A1 (ru) Новая композиция
AR008536A1 (es) Utilizacion de la tienilciclohexilamina bajo forma racemica, de diastereoisomeros o de enantiomeros sustancialmente puros, sola o en asociacioncon otras sustancias de actividad farmaceutica para preparar un medicamento destinado a limitar o inhibir los efectos debidos a productos neurotoxicos o neur

Legal Events

Date Code Title Description
FG Grant, registration